Nanobiotix SA
PAR:NANO

Watchlist Manager
Nanobiotix SA Logo
Nanobiotix SA
PAR:NANO
Watchlist
Price: 3.5 EUR -1.63% Market Closed
Market Cap: 165.9m EUR
Have any thoughts about
Nanobiotix SA?
Write Note

Nanobiotix SA
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nanobiotix SA
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Nanobiotix SA
PAR:NANO
Other Current Liabilities
€37.9m
CAGR 3-Years
12%
CAGR 5-Years
46%
CAGR 10-Years
46%
Valneva SE
PAR:VLA
Other Current Liabilities
€29.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Other Current Liabilities
€6.3m
CAGR 3-Years
76%
CAGR 5-Years
18%
CAGR 10-Years
1%
Inventiva SA
PAR:IVA
Other Current Liabilities
€2.2m
CAGR 3-Years
-2%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Other Current Liabilities
€18.7m
CAGR 3-Years
12%
CAGR 5-Years
15%
CAGR 10-Years
23%
OSE Immunotherapeutics SA
PAR:OSE
Other Current Liabilities
€2.9m
CAGR 3-Years
-8%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
No Stocks Found

Nanobiotix SA
Glance View

Market Cap
164.9m EUR
Industry
Biotechnology

Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 100 full-time employees. The company went IPO on 2012-10-29. The firm is engaged in developing nanoparticle technology. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The firm develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) plays a seminal role in the potential cure and gives the systemic treatment a better chance to increase life expectancy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

NANO Intrinsic Value
5.23 EUR
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Nanobiotix SA's Other Current Liabilities?
Other Current Liabilities
37.9m EUR

Based on the financial report for Jun 30, 2024, Nanobiotix SA's Other Current Liabilities amounts to 37.9m EUR.

What is Nanobiotix SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
46%

Over the last year, the Other Current Liabilities growth was 61%. The average annual Other Current Liabilities growth rates for Nanobiotix SA have been 12% over the past three years , 46% over the past five years , and 46% over the past ten years .

Back to Top